
Pulmonary Hypertension - StatPearls - NCBI Bookshelf
2024年5月1日 · Pulmonary hypertension encompasses a heterogeneous group of disorders with the common feature of elevated pulmonary artery pressures. Patients often present with worsening dyspnea on exertion, with signs of right heart strain or failure.
Management of Pulmonary Arterial Hypertension - PMC
This review focuses on the therapeutic management and individualized approach to Group 1 pulmonary arterial hypertension (PAH), utilizing Food and Drug Administration-approved PAH-specific therapies and various interventional and surgical options ...
肺动脉高压(PAH)的亚组都有哪些? - MedSci.cn
门静脉高压相关的 PAH(1.4.3 组) 门静脉高压症,定义为与门静脉高压症相关的 PAH,可发生于肝硬化门静脉高压症、无肝硬化的门静脉周围纤维化、门静脉 血栓 形成、肝静脉硬化和先天性门静脉循环异常的患者。 当存在肝硬化时,门脉肺动脉高压的生存率更差。
The latest definition and classification of pulmonary hypertension
2024年9月1日 · In recent classification systems, pulmonary arterial hypertension (PAH) (Group 1) is that subset with pulmonary arteriopathy causing elevated pulmonary vascular resistance. PAH encompasses several different sub-groups, including idiopathic and heritable PAH as well as congenital heart disease (CHD) related PH [1].
New Drugs and Therapies in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, progressive, pan vasculopathy affecting the pulmonary vasculature, with predominant pathology initiated in the pre-capillary pulmonary vascular tree, culminating in an elevated pulmonary vascular load [1].
Pulmonary Hypertension Definition, Classification, and ... - JACC: Asia
Pulmonary hypertension (PH) is caused by a range of conditions and is important to recognize as it is associated with increased mortality. Pulmonary arterial hypertension refers to a group of PH subtypes affecting the distal pulmonary arteries for which effective treatment is available.
Pulmonary Arterial Hypertension: Pathophysiology and Treatment
Pulmonary arterial hypertension (PAH), the first category of pulmonary hypertension, is a chronic and progressive disorder characterised by angioproliferative vasculopathy in the pulmonary arterioles, leading to endothelial and smooth muscle proliferation and dysfunction, inflammation and thrombosis.
Pulmonary Arterial Hypertension - The New England Journal of Medicine
2021年12月15日 · Pulmonary hypertension is a syndrome characterized by marked remodeling of the pulmonary vasculature and a progressive rise in the pulmonary vascular load, leading to hypertrophy and...
多环芳香烃 - 维基百科,自由的百科全书
2023年10月9日 · 多环芳香烃 (英语: Polycyclic Aromatic Hydrocarbons,简称 PAH 或 PAHs)又称 多环性芳香化合物 或 多环芳香族碳氢化合物,其化学结构式有100多种 [1]。 它是一种 芳香族碳氢化合物 (芳香烃),由不包含杂环或取代基的 芳香环 所组成;其中结构最简单的是具有两个芳环的 萘,以及三环化合物 蒽 和 菲。 多环芳香烃中有很多是已知或潜在的 致癌物质。 三环以上的多环性芳香化合物在水中具有低 溶解度 和低 蒸汽压,当 分子量 上升, 溶解度 和 …
Pulmonary Hypertension: A Brief Guide for Clinicians
2020年9月1日 · Pulmonary arterial hypertension is divided into 7 subgroups: idiopathic PAH (group 1.1), heritable PAH (group 1.2), drug- and toxin-induced PAH (group 1.3), PAH associated with various conditions including connective tissue diseases, HIV infection, portal hypertension, and congenital heart disease (group 1.4), PAH in long-term responders to ...
- 某些结果已被删除